get your facts straight angelo
first of all, amgen is not a one product company. neupogen and epogen are two blockbuster drugs. true, the growth rate has been stagnant lately, but if -an a big if- leptin (amgen's obesity-controlling product) gets fda approval, amgen's market cap of 13 billio - not 20 billion- will triple in a short time.
personally, i don't think there is any reason to invest in biotech presently. the sector has been full of empty promises. but when th big guns start rolling their dough in biotech in the next millenium, i will be there bettin three quarters of my ranch, in the meantime, go ORBI, go IDTC, go PSFT, go CNCX, go SAPHY, go SEBL. |
